PDCD1
Programmed cell death protein 1
Also known as: CD279, hSLE1, PD-1, PD1, PDCD1_HUMAN, SLEB2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q15116
- Gene
- PDCD1
- Ensembl
- ENSG00000188389
- Chromosome
- 2
- Canonical length
- 288 aa
- Protein class
- CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters
OverviewNCBI Gene
Programmed cell death protein 1 (PDCD1) is an immune-inhibitory receptor expressed in activated T cells; it is involved in the regulation of T-cell functions, including those of effector CD8+ T cells. In addition, this protein can also promote the differentiation of CD4+ T cells into T regulatory cells. PDCD1 is expressed in many types of tumors including melanomas, and has demonstrated to play a role in anti-tumor immunity. Moreover, this protein has been shown to be involved in safeguarding against autoimmunity, however, it can also contribute to the inhibition of effective anti-tumor and anti-microbial immunity. [provided by RefSeq, Aug 2020]
Canonical amino-acid sequenceUniProt
288 residues, UniProt reviewed canonical sequence.
>Q15116|PDCD1
1 MQIPQAPWPV VWAVLQLGWR PGWFLDSPDR PWNPPTFSPA LLVVTEGDNA TFTCSFSNTS
61 ESFVLNWYRM SPSNQTDKLA AFPEDRSQPG QDCRFRVTQL PNGRDFHMSV VRARRNDSGT
121 YLCGAISLAP KAQIKESLRA ELRVTERRAE VPTAHPSPSP RPAGQFQTLV VGVVGGLLGS
181 LVLLVWVLAV ICSRAARGTI GARRTGQPLK EDPSAVPVFS VDYGELDFQW REKTPEPPVP
241 CVPEQTEYAT IVFPSGMGTS SPARRGSADG PRSAQPLRPE DGHCSWPLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PDCD1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.53
- Highest tissue expression
- 15 nTPM
Expression across tissuesHPA
Tissue
- lymph node: 15 nTPM
- spleen: 6.7 nTPM
- heart muscle: 6.4 nTPM
- tonsil: 3.8 nTPM
- small intestine: 3.6 nTPM
- appendix: 3 nTPM
Single-cell type
- t-cells: 2 nCPM
- brain inhibitory neurons: 0.2 nCPM
- distal convoluted tubule cells: 0.2 nCPM
- b-cells: 0.1 nCPM
- lactotrophs: 0.1 nCPM
- loop of henle epithelial cells: 0.1 nCPM
Immune cell
- memory CD8 T-cell: 12 nTPM
- memory CD4 T-cell: 8.7 nTPM
- MAIT T-cell: 4.8 nTPM
- gdT-cell: 4.4 nTPM
- T-reg: 4.3 nTPM
- total PBMC: 2.1 nTPM
Brain region
- midbrain: 3.1 nTPM
- thalamus: 1 nTPM
- choroid plexus: 0.7 nTPM
- pons: 0.6 nTPM
- white matter: 0.6 nTPM
- basal ganglia: 0.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PDCD1.
Disease | AllUniProt
Conditions PDCD1 is implicated in, by any mechanism.
- Autoimmune disease, multisystem, infantile-onset, 4 (ADMIO4) MIM:621004
ReferencesPubMed · IEDB
Publications for PDCD1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
4 publications
- Pembrolizumab-induced thrombotic thrombocytopenic purpura.
2020 · J Oncol Pharm Pract · RCR 1.5 · 31 citations - Prevalence and Associated Factors for Thyroid Dysfunction Among Patients On Targeted Therapy for Cancers: A Single-Center Study from Thailand.
2023 · J ASEAN Fed Endocr Soc · RCR 0.8 · 4 citations - Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events.
2024 · Data Brief · RCR 0.2 · 1 citations - Endocrine Crisis Triggered by Pembrolizumab: A Case of Acute-Onset Diabetes With Diabetic Ketoacidosis.
2025 · Cureus
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.66
- gnomAD pLI
- 0.42
- gnomAD missense Z
- 1.29
- DepMap mean gene effect
- -0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adaptive immune response
- apoptotic process
- B cell apoptotic process
- humoral immune response
- negative regulation of B cell apoptotic process
- negative regulation of immune response
- negative regulation of inflammatory response
- negative regulation of T cell activation
- negative regulation of T cell mediated immune response to tumor cell
- negative regulation of T cell receptor signaling pathway
- positive regulation of T cell apoptotic process
- regulation of immune response
- negative regulation of tolerance induction
- regulatory T cell apoptotic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PDCD1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PDCD1 as an antibody target. Whether an autoantibody or antibody against PDCD1 could matter depends on whether native PDCD1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PDCD1 is annotated at the cell surface, where native PDCD1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label PDCD1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...